{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:51:19Z","timestamp":1789771879149,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02218-9","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:25:20Z","timestamp":1782451520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Ahmed","family":"Emara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa H.","family":"Elkholy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Fayez","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza A.","family":"Abdul-Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Al Diab Al","family":"Azzawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalhakim","family":"Shubietah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"2218_CR1","doi-asserted-by":"publisher","first-page":"102882","DOI":"10.1016\/j.pmedr.2024.102882","volume":"46","author":"ANMS Islam","year":"2024","unstructured":"Islam ANMS, Sultana H, Nazmul Hassan Refat M, Farhana Z, Abdulbasah Kamil A, Meshbahur Rahman M. The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: A meta-analysis. Prev Med Rep. 2024;46:102882. PMID: 39290257IF: 2.4 Q2 B3; PMCID: PMC11406007IF: 2.4 Q2 B3.","journal-title":"Prev Med Rep"},{"key":"2218_CR2","unstructured":"World Health Organization. 2024. Obesity and overweight [WWW Document]. World Health Organization. URL https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight# (accessed 10.14.21)."},{"key":"2218_CR3","unstructured":"International Diabetes Federation. Diabetes facts and figures [Internet]. 2025. Available from:https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/"},{"key":"2218_CR4","doi-asserted-by":"publisher","unstructured":"Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6. https:\/\/doi.org\/10.1038\/nature05482. PMID: 17167471IF: 48.5 Q1 B1.","DOI":"10.1038\/nature05482"},{"key":"2218_CR5","doi-asserted-by":"publisher","unstructured":"Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005 Apr 16\u201322;365(9468):1415-28. https:\/\/doi.org\/10.1016\/S0140-6736(05)66378-7. PMID: 15836891IF: 88.5 Q1 B1.","DOI":"10.1016\/S0140-6736(05)66378-7"},{"issue":"4","key":"2218_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s13300-023-01384-7","volume":"14","author":"KS Boye","year":"2023","unstructured":"Boye KS, Ford JH, Thieu VT, Lage MJ, Terrell KA. The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes. Diabetes Ther. 2023;14(4):709\u201321. https:\/\/doi.org\/10.1007\/s13300-023-01384-7 . Epub 2023 Feb 23. PMID: 36820959IF: 2.6 Q3 B3; PMCID: PMC9948793IF: 2.6 Q3 B3.","journal-title":"Diabetes Ther"},{"issue":"4","key":"2218_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jamacardio.2018.0022","volume":"3","author":"SS Khan","year":"2018","unstructured":"Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2018.0022.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"2218_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2337\/dc16-2736","volume":"40","author":"M Abdul-Ghani","year":"2017","unstructured":"Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? Diabetes Care. 2017;40(7):813\u201320. https:\/\/doi.org\/10.2337\/dc16-2736.","journal-title":"Diabetes Care"},{"issue":"8","key":"2218_CR9","doi-asserted-by":"publisher","first-page":"e24017","DOI":"10.2196\/24017","volume":"23","author":"N Liu","year":"2021","unstructured":"Liu N, Birstler J, Venkatesh M, Hanrahan L, Chen G, Funk L. Obesity and BMI cut points for associated comorbidities: electronic health record study. J Med Internet Res. 2021;23(8):e24017. https:\/\/doi.org\/10.2196\/24017.","journal-title":"J Med Internet Res"},{"issue":"7","key":"2218_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1185\/03007995.2016.1168291","volume":"32","author":"K Iglay","year":"2016","unstructured":"Iglay K, Hannachi H, Howie PJ, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243\u201352. https:\/\/doi.org\/10.1185\/03007995.2016.1168291.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"2218_CR11","doi-asserted-by":"publisher","first-page":"107730","DOI":"10.1016\/j.jdiacomp.2020.107730","volume":"34","author":"KS Boye","year":"2020","unstructured":"Boye KS, Lage MJ, Terrell K. Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. J Diabetes Complications. 2020;34(12):107730. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107730.","journal-title":"J Diabetes Complications"},{"issue":"5","key":"2218_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000480525","volume":"10","author":"DR Leitner","year":"2017","unstructured":"Leitner DR, Fr\u00fchbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies\u2014EASO can lead the way. Obes Facts. 2017;10(5):483\u201392. https:\/\/doi.org\/10.1159\/000480525.","journal-title":"Obes Facts"},{"issue":"6","key":"2218_CR13","doi-asserted-by":"publisher","first-page":"e70134","DOI":"10.1002\/edm2.70134","volume":"8","author":"RK Pandey","year":"2025","unstructured":"Pandey RK, Jan M, Mohammad A, Jawaid KA, Naveed M, Abid MA, Amir AB, Ahmed S, Safiullah M, Bhatti MI, Iftikhar S, Saddique MN, Alfalh W, Omar RMB, Abu Dawood H. Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab. 2025;8(6):e70134. https:\/\/doi.org\/10.1002\/edm2.70134 . PMID: 41296780IF: 2.6 Q3 B4; PMCID: PMC12653021IF: 2.6 Q3 B4.","journal-title":"Endocrinol Diabetes Metab"},{"key":"2218_CR14","doi-asserted-by":"publisher","first-page":"10449","DOI":"10.3390\/ijms241310449","volume":"24","author":"M-S Popoviciu","year":"2023","unstructured":"Popoviciu M-S, P\u0103duraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of GLP-\u00ad 1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023;24:10449. https:\/\/doi.org\/10.3390\/ijms241310449.","journal-title":"Int J Mol Sci"},{"key":"2218_CR15","doi-asserted-by":"publisher","unstructured":"Ghusn W, Hurtado MD. Glucagon-Like Receptor-1 Agonists for Obesity: Weight Loss Outcomes, Tolerability, Side Effects, and Risks, Obesity Pillars 12 (2024): 100127. https:\/\/doi.org\/10.1016\/j.obpill.2024.100127.","DOI":"10.1016\/j.obpill.2024.100127"},{"key":"2218_CR16","doi-asserted-by":"publisher","first-page":"1099880","DOI":"10.3389\/fnut.2023.1099880","volume":"10","author":"K Mokgalaboni","year":"2023","unstructured":"Mokgalaboni K, Phoswa WN. Corchorus olitorius extract exhibit anti-hyperglycemic and anti-inflammatory properties in rodent models of obesity and diabetes mellitus. Front Nutr. 2023;10:1099880. https:\/\/doi.org\/10.3389\/fnut.2023.1099880.","journal-title":"Front Nutr"},{"issue":"47","key":"2218_CR17","doi-asserted-by":"publisher","first-page":"29959","DOI":"10.1073\/pnas.2014879117","volume":"117","author":"T Kawai","year":"2020","unstructured":"Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M, Nagao S, Wainscott DB, Showalter AD, Droz BA, Kobilka TS, Coghlan MP, Willard FS, Kawabe Y, Kobilka BK, Sloop KW. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020;117(47):29959\u201367. https:\/\/doi.org\/10.1073\/pnas.2014879117 . Epub 2020 Nov 11. PMID: 33177239IF: 9.1 Q1 B1; PMCID: PMC7703558IF: 9.1 Q1 B1.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2218_CR18","unstructured":"Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Robins D. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472\u2013483. doi: 10.1016\/S0140-6736(23)01302-8IF: 88.5 Q1 B1. Epub 2023 Jun 24. Erratum in: Lancet. 2023;402(10404):774. . Erratum in: Lancet. 2024;403(10446):2786. doi: 10.1016\/S0140-6736(24)01314-XIF: 88.5 Q1 B1. PMID: 37369232IF: 88.5 Q1 B1."},{"issue":"10522","key":"2218_CR19","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","volume":"406","author":"DB Horn","year":"2026","unstructured":"Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, Aberle J, Bain SC, Allen S, Sarker E, Wu Q, Stefanski A, Jouravskaya I. ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026;406(10522):2927\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(25)02165-8 . Epub 2025 Nov 20. PMID: 41275875IF: 88.5 Q1 B1.","journal-title":"Lancet"},{"issue":"11","key":"2218_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fern\u00e1ndez Land\u00f3 L, Denning M, Ludwig L, Chen Y. ACHIEVE-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1065\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2505669. Epub 2025 Jun 21. PMID: 40544435IF: 78.5 Q1 B1.","journal-title":"N Engl J Med"},{"key":"2218_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Reviews. 2021;10:89.","journal-title":"Syst Reviews"},{"key":"2218_CR22","unstructured":"Higgins J et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (2024)."},{"key":"2218_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:1\u201310.","journal-title":"Syst Rev"},{"key":"2218_CR24","doi-asserted-by":"publisher","unstructured":"Sterne JAC et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJl4898\u2013l4898 (2019) https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2218_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"issue":"3","key":"2218_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785\u201394.","journal-title":"Biometrics"},{"issue":"10400","key":"2218_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Nauck MA, Van J, et al. Orforglipron for the treatment of type 2 diabetes. Lancet. 2023;402(10400):472\u201383.","journal-title":"Lancet"},{"issue":"10","key":"2218_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Astrup A, Fujioka K, et al. Daily oral orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877\u201388.","journal-title":"N Engl J Med"},{"issue":"7","key":"2218_CR29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc22-1993","volume":"46","author":"E Pratt","year":"2023","unstructured":"Pratt E, Botros FT, Guja C, et al. Pharmacokinetics, safety, and tolerability of orforglipron (LY3502970). Diabetes Care. 2023;46(7):1335\u201342.","journal-title":"Diabetes Care"},{"issue":"10278","key":"2218_CR30","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"MJ Davies","year":"2021","unstructured":"Davies MJ, Bergenstal R, Bode B, et al. Efficacy of semaglutide 2.4\u00a0mg once weekly in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"key":"2218_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"2218_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults With Overweight or Obesity. New Engl Jour-nal Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"New Engl Jour-nal Med"},{"issue":"3","key":"2218_CR33","first-page":"210","volume":"32","author":"JH Bae","year":"2023","unstructured":"Bae JH, Kim HJ, Cho JH. Oral glucagon-like peptide-1 receptor agonists: a new era. J Obes Metab Syndr. 2023;32(3):210\u201322.","journal-title":"J Obes Metab Syndr"},{"issue":"1","key":"2218_CR34","first-page":"35","volume":"67","author":"T Karagiannis","year":"2024","unstructured":"Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with oral GLP-1 receptor agonists. Diabetologia. 2024;67(1):35\u201348.","journal-title":"Diabetologia"},{"key":"2218_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of Action and Therapeutic Applica- tion of Glucagon-Like Peptide-1. Cell Metabol. 2018;27:740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metabol"},{"issue":"3","key":"2218_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying GLP-1 receptor agonists: a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19(3):336\u201347.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2218_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2218_CR38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/dom.15377","volume":"26","author":"T Kadowaki","year":"2024","unstructured":"Kadowaki T, Isendahl J, Khalid U, et al. Efficacy and safety of orforglipron in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2024;26(3):851\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"2218_CR39","first-page":"1342681","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Zhang Y, Wang Y, et al. Efficacy and safety of orforglipron: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024;15:1342681.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2218_CR40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/14740338.2023.2193391","volume":"22","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhang M, Zhang Y, et al. Hypoglycemia risk associated with glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis. Expert Opin Drug Saf. 2023;22(8):723\u201335.","journal-title":"Expert Opin Drug Saf"},{"key":"2218_CR41","doi-asserted-by":"publisher","unstructured":"Hageen AW, Gadelmawla AF, Saleh AO. The gastrointestinal safety of orforglipron, a GLP-1 receptor agonist, in adults with or without type 2 diabetes: A network meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab https:\/\/doi.org\/10.1002\/edm2.70222","DOI":"10.1002\/edm2.70222"},{"issue":"1","key":"2218_CR42","first-page":"9","volume":"41","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, et al. Effect of GLP-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Diabetes Metab. 2015;41(1):9\u201318.","journal-title":"Diabetes Metab"},{"issue":"1","key":"2218_CR43","doi-asserted-by":"publisher","first-page":"e102018","DOI":"10.7759\/cureus.102018","volume":"18","author":"M Tantoush","year":"2026","unstructured":"Tantoush M, Almaghrabi Y, Abusbaeh A, Ahmed N, Tantush A, Ben Hamida B, Sagher M, Sager M, Abouslima A, Elbahnasawy SE, Elhady MM, Gamal MH. Comparative efficacy and safety of different orforglipron doses in patients with type 2 diabetes mellitus and obesity: A systematic review and network meta-analysis. Cureus. 2026;18(1):e102018. https:\/\/doi.org\/10.7759\/cureus.102018.","journal-title":"Cureus"},{"issue":"2","key":"2218_CR44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(19)30358-4","volume":"8","author":"VD Heuvelman","year":"2020","unstructured":"Heuvelman VD, van Raalte DH, Smits MM. Effects of GLP-1 receptor agonists on heart rate. Lancet Diabetes Endocrinol. 2020;8(2):105.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02218-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02218-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02218-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:06:23Z","timestamp":1789081583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02218-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02218-9","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that no artificial intelligence was used.","order":2,"name":"Ethics","label":"AI use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"196"}}